References of "Rixhon, M"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLearning from recombinant GH treatment in obesity
Vandeva, S.; Rixhon, M.; Tichomirova, M. A. et al

in Obesity and Metabolism (2009), 5(3/4), 156-166

Obese and untreated growth hormone deficiency (GHD) patients have a number of similar clinical and biological abnormalities. Treatment with recombinant human growth hormone (rhGH) in GHD patients has ... [more ▼]

Obese and untreated growth hormone deficiency (GHD) patients have a number of similar clinical and biological abnormalities. Treatment with recombinant human growth hormone (rhGH) in GHD patients has proven effective in beneficially modulating body composition and certain cardiovascular risk factors, thus leading to the hypothesis that administration of rhGH in obese patients could show similar beneficial results. Hyperinsulinism and increased free fatty acid levels are the main factors causing reduced GH release in the setting of obesity. We reviewed the outcomes of 25 adult and paediatric clinical studies carried out in 1987-2009 that examined the effects of rhGH administration in the obese state. Body composition showed mainly a reduction in visceral abdominal fat, whereas total bodyweight increased or remained unchanged. Effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients were heterogeneous. The increasing burden of obesity on one hand, the absence of definitive medical treatment on the other, give rise to grounds for considering rhGH as a possible therapeutic option if not in the general obese population, at least in patients with higher risk of cardiovascular morbidity and mortality. [less ▲]

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailCurrent and future perspectives on Recombinant GH for the treatment of Obesity
Rixhon, M.; Tikhomirova, M. A.; Tamagno, G. et al

in Expert Review of Endocrinology & Metabolism (2008), 3(1), 75-89

The similarities between patients with untreated growth hormone (GH) deficiency and those with the cardiometabolic syndrome and the beneficial effects of recombinant human GH (rhGH) on body composition ... [more ▼]

The similarities between patients with untreated growth hormone (GH) deficiency and those with the cardiometabolic syndrome and the beneficial effects of recombinant human GH (rhGH) on body composition have led to the hypothesis that rhGH treatment may have utility in obesity. GH release is reduced in the setting of obesity, primarily due to hyperinsulinism and increased free fatty acid levels. We reviewed the outcomes of 23 clinical studies carried out between 1987 and 2006 that examined the effects of rhGH administration in the obese state. Typically, changes in overall body weight do not occur with rhGH therapy; however, assessment of body composition demonstrates reductions in visceral abdominal fat. Data on the effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients are less clear-cut, with a subset of studies showing a beneficial effect and others a neutral effect. Given the increasing burden of obesity in the general population and the current paucity of effective therapies, it is useful to consider the data on rhGH and obesity from a clinical perspective to highlight potential treatment strategies that harness the somatotropic axis. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailHigh prevalence of pituitary adenomas: A cross-sectional study in the province of Liege, Belgium
Daly, Adrian ULg; Rixhon, M.; Adam, Christelle et al

in Journal of Clinical Endocrinology and Metabolism (2006), 91(12), 4769-4775

Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce. Objective: The objective of the study was to ... [more ▼]

Context: Prevalence data are important for assessing the burden of disease on the health care system; data on pituitary adenoma prevalence are very scarce. Objective: The objective of the study was to measure the prevalence of clinically relevant pituitary adenomas in a well-defined population. Design: This was a cross-sectional, intensive, case-finding study performed in three regions of the province of Liège, Belgium, to measure pituitary adenoma prevalence as of September 30, 2005. Setting: The study was conducted in specialist and general medical practitioner patient populations, referral hospitals, and investigational centers. Methods: Three demographically and geographically distinct districts of the province of Liège were delineated precisely using postal codes. Medical practitioners in these districts were recruited, and patients with pituitary adenomas under their care were identified. Diagnoses were confirmed after retrieval of clinical, hormonal, radiological, and pathological data; full demographic and therapeutic follow-up data were collected in all cases. Results: Sixty-eight patients with clinically relevant pituitary adenomas were identified in a population of 71,972 individuals; the mean (± SD) prevalence was 94 ± 19.3 cases per 100,000 population (95% confidence interval, 72.2 to 115.8). The group was 67.6% female and had a mean age at diagnosis of 40.3 yr; 42.6% had macroadenomas and 55.9% underwent surgery. Prolactinomas comprised 66% of the group, with the rest having nonsecreting tumors (14.7%), somatotropinomas (13.2%), or Cushing’s disease (5.9%); 20.6% had hypopituitarism. Conclusion: The prevalence of pituitary adenomas in the study population (one case in 1064 individuals) was more than 3.5–5 times that previously reported. This increased prevalence may have important implications when prioritizing funding for research and treatment of pituitary adenomas. [less ▲]

Detailed reference viewed: 29 (8 ULg)
See detailApproaching the true prevalence of pituitary tumors
Beckers, Albert ULg; Adam, C.; Ciccarelli, A. et al

in ENEA congress : Napoli, April 2004 (2004, April)

Detailed reference viewed: 11 (0 ULg)
See detailApproaching the true prevalence of pituitary tumors
Beckers, Albert ULg; Ciccarelli, A.; Daly, Adrian ULg et al

in 12th International Congress of Endocrinology - Abstract book (2004)

Detailed reference viewed: 6 (0 ULg)
See detailUne approche de la vraie prévalence des tumeurs hypophysaires
Beckers, Albert ULg; Ciccarelli, A.; Daly, Adrian ULg et al

in XXIème Congrès de la Société Française d'Endocrinologie - Abstract book (2004)

Detailed reference viewed: 9 (3 ULg)